A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. by SD Gore SD, et al.
Myelodysplastic Syndromes Articles
haematologica | 2013; 98(7) 1067
Introduction
Thirty percent of patients with myelodysplastic syndromes
(MDS) present with higher-risk disease (International
Prognostic Scoring System1 [IPSS] intermediate-2 or high)
with an over 60% risk of progression to acute myelogenous
leukemia (AML) and poor overall survival (OS).2,3 The pri-
mary goal of treatment for higher-risk MDS is prolonging OS
by altering the natural disease course.4,5 Because treatment-
related effects on OS may require years to measure, hemato-
logic response has been the primary end point in most MDS
clinical studies. Using treatment experience from AML, the
general view has been that complete or partial remission (CR
or PR) is a prerequisite for prolonged OS.6
The phase III randomized AZA-001 trial demonstrated that
azacitidine (Vidaza®, Celgene Corporation, Summit, NJ,
USA) significantly prolongs OS in higher-risk MDS compared
with conventional care (CCR) (hazard ratio [HR] 0.58
[95%CI: 0.43-0.77], P<0.001).7  In the AZA-001 study, signif-
icantly more patients achieved hematologic improvement
(HI)5 with azacitidine than with CCR (49% vs. 29%, respec-
tively, P<0.0001). The paradigm that CR or PR is necessary to
prolong OS is being challenged.4 This study was designed to
assess whether CR or PR are obligate responses for improved
OS with azacitidine and whether a best response of HI might
be associated with improved OS as well. Analyses of OS by
treatment response category can be misleading if an inappro-
priate statistical approach is used.9,10 To minimize potential
biases, we used two approaches to assess the relationship
between treatment response and OS in the AZA-001 study: a
multivariate Cox regression analysis with response category
as a time-varying covariate, and landmark analyses examin-
ing the response-survival relationship with response catego-
rized at fixed time points.9-11
Design and Methods
AZA-001 (ClinicalTrials.gov Identifier:00071799) study design is
reported in detail elsewhere.7 
All patients provided written, informed consent before participat-
ing in the study. A multivariate Cox regression analysis with response
as a time-varying covariate evaluated the relationship between hema-
tologic response and OS. CR, PR, HI, stable disease (SD), and progres-
sion were defined by IWG MDS 2000 criteria.5 Stable Disease was
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The phase III AZA-001 study established that azacitidine significantly improves overall survival compared with
conventional care regimens (hazard ratio 0.58 [95% confidence interval 0.43-0.77], P<0.001). This analysis was
conducted to investigate the relationship between treatment response and overall survival. AZA-001 data were
analyzed in a multivariate Cox regression analysis with response as a time-varying covariate. Response categories
were “Overall Response” (defined as complete remission, partial remission, or any hematologic improvement) and
“Stable Disease” (no complete or partial remission, hematologic improvement, or progression) or “Other” (e.g. dis-
ease progression). Achieving an Overall Response with azacitidine reduced risk of death by 95% compared with
achieving an Overall Response with the conventional care regimens (hazard ratio 0.05 [95%CI: 0.01-0.43],
P=0.006). Sensitivity analyses indicated that significantly improved overall survival remained manifest for patients
with a hematologic improvement who had never achieved complete or partial remission (hazard ratio 0.19
[95%CI: 0.08–0.46], P<0.001). Stable Disease in both azacitidine-treated and conventional care-treated patients
was also associated with a significantly reduced risk of death (hazard ratio 0.09, [95%CI: 0.06–0.15]; P<0.001).
These results demonstrate azacitidine benefit on overall survival compared with conventional care regimens in
patients with higher-risk myelodysplastic syndromes who achieve hematologic response but never attain com-
plete or partial remission, in addition to the survival advantage conferred by achievement of complete or partial
remission. This study was registered with clinicaltrials.gov (NCT00071799).
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defined as no evidence of progression without  HI. Patient
responses (CR and PR) were reviewed by an independent review
committee (IRC) of international MDS experts blinded to treat-
ment assignment, and an HI response was determined program-
matically.
Response was classified in 3 categories: Overall Response (HI,
PR, or CR), Stable Disease (without HI), and Other (e.g. disease
progression). HI, PR, and CR were grouped in Overall Response
because HI could be evaluated twice monthly while IRC-assessed
PR or CR (requiring bone marrow samples) could be evaluated
only every four months and we wanted to capture changes in
response as soon as they occurred. 
Response was evaluated as a time-varying covariate, with
patients’ response classification changing each time clinical status
changed. Thus, a patient starting study with Stable Disease,
achieving HI at Day 84, PR at Day 195, and sustaining PR until
Day 581 would enter the model as Stable Disease for Days 0-83,
HI for Days 84-194, and PR for Days 195-581. 
OS was evaluated using a Cox proportional hazards model
stratified by FAB and IPSS, including treatment as a factor. Time-
varying covariates of Overall Response and Stable Disease, and
terms for Overall Response-by-treatment and Stable Disease-by-
treatment, were added to the model. HR and associated 95% con-
fidence intervals (CI) are reported from this model; HR and P value
were adjusted for presence of all factors. Sensitivity analyses eval-
uated the relationship between HI without an investigator-
assessed response of CR or PR and OS. (IRC-adjudicated CR+PR
rates at any time were small; because investigator-reported
CR+PR rates were higher, they increased the probability of detect-
ing whether CR and PR were driving the OS benefit.) The sensi-
tivity analysis evaluated OS in patients with a PR or CR during the
study, and in those with an HI as best response (i.e. without an
investigator-reported PR or CR on-study). A similar method was
used to assess the relationship between OS and Stable Disease.
Landmark (“snapshot”) analyses were performed to corroborate
the Cox regression analysis and to avoid biases inherent in classi-
fying patients by best response during study. Landmark analyses
evaluated the relationship between OS and response at three, six,
and nine months. Median OS and 2-year OS rates were estimated
using Kaplan-Meier methods. HRs and 95% CIs were from a Cox
proportional hazards model and the effect of treatment on OS
within response groups was evaluated using a 2-sided log rank
test. Exploratory logistical regression analyses investigated differ-
ences in baseline clinical characteristics between: 1) patients in the
azacitidine and CCR groups with Stable Disease as best response
at six months; and 2) patients (in both treatment arms) who
achieved an Overall Response and patients who maintained Stable
Disease over the 9-month period.
Results
Demographic and disease characteristics of the 358
patients (azacitidine n=179, CCR n=179) included in AZA-
001 and patient disposition are reported elsewhere.7
Median follow up was 21.1 months. Patients received a
median of 9 azacitidine treatment cycles (range 1-39), 4.5
LDAC cycles (1-15; n=49), one intensive chemotherapy
cycle (1-3; n=25), or supportive care for a median 6.2
months (range 0.2-25.8; n=105).7
Survival in patients with Overall Response
The multivariate Cox proportional hazard model using
response as a time-varying covariate indicated that achiev-
ing Overall Response (HI, PR, or CR) with either azaciti-
dine or CCR was associated with an 84% reduced risk of
death (HR 0.16, 95%CI: 0.07-0.37; P<0.0001) compared
with no Overall Response (Table 1). However, the
response-by-treatment interaction analysis showed that
achieving Overall Response with azacitidine was associat-
ed with a 95% reduced risk of death compared with
achieving Overall Response with CCR (HR 0.05, 95%CI:
0.01-0.43; P=0.006). In the multivariate model, treatment
group alone as a factor in the model was not significant
(P=0.26), indicating that the observed significant survival
benefit with azacitidine compared with CCR is mediated
through the other factors in the model (i.e. achievement of
Overall Response). Sensitivity analysis demonstrated that
achievement of HI without investigator-reported response
of CR or PR at any time during the study remained asso-
ciated with improved OS (Table 2). (Investigator-reported
response of CR or PR at any time was achieved by 51
azacitidine-treated patients [29%] and 21 CCR patients
[12%].7) The treatment effect of azacitidine versus CCR for
improved OS remained significant in this model (HR 0.07,
95%CI: 0.01-0.68; P=0.021).
Landmark analyses supported results of the multivariate
analysis (Figure 1). Median OS within the Overall
Response group was not reached in patients receiving
azacitidine at any landmark, while median OS in the CCR
group ranged from 16.6 to 21.5 months. HRs for OS with
azacitidine versus CCR ranged from 0.26 to 0.31.
Estimated OS rates at two years in patients who achieved
Overall Response were approximately 2-fold higher in the
azacitidine group at each landmark than in the CCR group
(73-83% vs. 33-42%, respectively) (Table 3).
At three months, 56 azacitidine patients and 30 CCR
patients had achieved an Overall Response (Figure 3).
Proportionately more patients in the azacitidine group
retained an Overall Response at six months (48 of 56,
86%) than did patients receiving CCR (15 of 30, 50%). Of
patients with an Overall Response at six months, 54 of 68
patients (79%) in the azacitidine group and 21 of 28 (75%)
in the CCR group retained an Overall Response at nine
months.
Survival in patients with Stable Disease
In the multivariate analysis, Stable Disease (without HI)
was associated with a 91% reduction in risk of death (HR
0.09, 95%CI: 0.06-0.15; P<0.0001) throughout the course
of the study (Table 1). The significant association between
Stable Disease and improved OS was not treatment-spe-
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Table 1. Overall survival: multivariate Cox regression analysis with response as
a time-varying covariate.
Final model Hazard ratio P value for 
(95% CI) factor in model*†
Overall response (HI, PR, or CR) 0.16 (0.07, 0.37) <0.0001
as time-varying covariate
Interaction term of overall response 0.05 (0.01, 0.43) 0.006
with treatment group (AZA vs. CCR)
Stable disease (no HI, PR, or CR) 0.09 (0.06, 0.15) <0.0001
as time-varying covariate
Treatment group (AZA vs. CCR) 1.19 (0.88, 1.61) 0.26‡
*From the Cox regression model stratified by FAB and IPSS. †Similar results were obtained using
the stratified Cox regression with terms ECOG PS, baseline LDH, baseline Hgb, number of RBC
transfusions in the 56 days before randomization, and the presence or absence of -7/del(7q)
abnormality. ‡Treatment group is not significant (P=0.26); the observed significant survival benefit
























cific, occurring with both azacitidine and CCR treatment.
Sensitivity analysis showed Stable Disease was associated
with significantly improved OS even when no investiga-
tor-reported CR or PR was achieved during the study
(Table 2). Similar results were obtained when the covari-
ates ECOG PS, LDH, and Hgb at baseline, number RBC
transfusions before randomization, and presence/absence
of -7/del(7q) abnormality were included in the model (data
not shown).
Results of landmark analyses were consistent with the
multivariate analysis: there was no statistically significant
difference in median OS between azacitidine and CCR
treatment groups for patients with Stable Disease as the
best response at three, six, or nine months (Figure 2, Table
3). Estimated 2-year OS rates in patients with Stable
Disease as best response at three months were 52% and
33% for azacitidine and CCR patients, respectively, and
rose to 84% and 63%, respectively, for patients with
Stable Disease as their best response at month 9 (Table 3).
Of 93 azacitidine patients and 92 CCR patients with
Stable Disease as their best response at three months,
approximately half (azacitidine 53%, CCR 45%) main-
tained Stable Disease at six months (Figure 3). Eighteen
azacitidine patients (19%) and 12 CCR patients (13%)
with Stable Disease at three months achieved an Overall
Response at six months, and 7 azacitidine patients (14%)
and no CCR patient with Stable Disease at six months
achieved an Overall Response by nine months. 
Univariate logistical regression analysis showed signifi-
cant differences in some hematologic indices at baseline
between the subgroups of patients in the azacitidine
(n=49) and CCR (n=41) treatment arms with Stable
Disease as their best response at six months (Online
Supplementary Table S1). In patients with available baseline
cytogenetic data, a significantly higher proportion of those
receiving azacitidine had abnormal (vs. normal) cytogenet-
ics: 52% vs. 29% of CCR patients, P=0.038 (data not
shown), and azacitidine patients had more frequent base-
line cytopenias. In addition, patients receiving azacitidine
had lower median platelet counts (68 vs. 107 x 109/L with
CCR; P=0.045) and 10% were platelet transfusion-depen-
dent, compared with none of the CCR patients. These
imbalances were not present at baseline in the overall ran-
domized cohorts in AZA-001.7 Two baseline characteris-
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Figure 1. Median survival in patients with
overall response (HI, PR, or CR) at 3-
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HR = 0.26 (95%CI: 0.13, 0.53)
P<0.001
AZA n=56; CCR n=30
AZA n=68; CCR n=28
AZA n=63; CCR n=21
HR = 0.31 (95%CI: 0.15, 0.65)
P=0.002







































tics remained significant in the multivariate model for OS:
number of cytopenias (P=0.007) and presence of abnormal
cytogenetics (P=0.016). Logistical regression analyses to
determine whether patients who achieved an Overall
Response at some point during the 9-month period had
different clinical characteristics at baseline than patients
who maintained Stable Disease as their best response
included 106 azacitidine patients (Overall Response, n=83;
Stable Disease, n=23) and 64 CCR patients (Overall
Response, n=43; Stable Disease, n=21). In both treatment
arms, a significantly higher proportion of patients who
were RBC transfusion-dependent at baseline achieved an
Overall Response rather than maintaining Stable Disease
when compared with patients who were transfusion-
independent at baseline. Logistical regression analyses to
determine whether patients who achieved an Overall
Response at some point during the 9-month period had
different clinical characteristics at baseline than patients
who maintained Stable Disease as their best response
included 106 azacitidine patients (Overall Response, n=83;
Stable Disease, n=23) and 64 CCR patients (Overall
Response, n=43; Stable Disease, n=21). In both treatment
arms, a significantly higher proportion of patients who
were RBC transfusion-dependent at baseline achieved an
Overall Response rather than maintaining Stable Disease
when compared with patients who were transfusion-
independent at baseline.
Discussion
Results of these analyses show that achieving Overall
Response (HI, CR, or PR) significantly improves OS in
patients with higher-risk MDS, with a strong treatment
effect favoring azacitidine over CCR. Azacitidine-treated
patients who achieved Overall Response had a 95%
reduced risk of death compared with CCR-treated
patients who achieved Overall Response. Sensitivity
analyses supported the significant OS benefit of Overall
Response in patients with HI (i.e. improvement of cytope-
nias) as best response, without ever achieving CR or PR.
Importantly, sensitivity analyses supported the significant
treatment benefit of azacitidine on OS in patients with HI
as a best response (93% reduced risk of death with azaci-
tidine vs. CCR). The significant response-by-treatment
interaction in patients with Overall Response favoring
azacitidine suggests that hematologic responses with
azacitidine are qualitatively different from those with
CCR. In addition, of all patients who maintained Stable
S.D. Gore et al.
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Figure 2. Median survival in patients with
stable disease as best response at 3-
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Disease as best response at six months, those who
received azacitidine had worse pre-treatment clinical char-
acteristics (increased abnormal cytogenetics, more trilin-
eage cytopenias) than those who received CCR, suggest-
ing sicker patients were able to maintain SD with azaciti-
dine. 
There are no definitive guidelines regarding when to
stop azacitidine treatment in patients who maintain Stable
Disease. Azacitidine, a DNA methyltransferase inhibitor,
requires multiple cycles to modulate clonal hematopoietic
abnormalities.15,16 This multivariate Cox regression analy-
sis suggests Stable Disease without HI may have OS ben-
efits in patients treated with azacitidine or CCR. Our
results also showed that with continued treatment, about
one-third of azacitidine-treated patients with Stable
Disease at three months will achieve Overall Response by
nine months; however, this should be interpreted cau-
tiously, since this is a retrospective analysis and by month
9 patient numbers were quite small. Recent MDS treat-
ment guidelines recommend a minimum of 6 azacitidine
treatment cycles in patients with higher-risk MDS with or
without an IWG response, and maintenance therapy for as
long as patients continue to benefit.14,17,18 Further study is
Azacitidine response and OS in higher-risk MDS
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Figure 3. Change in response with continued treatment in patients
with stable disease as best response.
Table 2. Sensitivity analyses of investigator-reported best responses of CR or PR versus best responses without CR or PR.
Final model Hazard ratio P value for factor 
(95% CI) in model*†
Overall response without investigator-reported response of PR or CR at any assessment 0.19 (0.08-0.46) 0.0002
(i.e., HI as best response)
Overall response WITH an investigator-reported response of PR or CR at 1 or more assessments 0.07 (0.01-0.55) 0.012
Interaction term of overall response with treatment group (AZA vs. CCR) 0.07 (0.01-0.68) 0.021
Stable disease WITHOUT investigator-reported response of PR or CR at any assessment 0.11 (0.06-0.17) < 0.0001
Stable disease WITH investigator-reported response of PR or CR at 1 or more assessment 0.02 (0.00-0.16) 0.0001
Treatment group (AZA vs. CCR) 1.20 (0.89-1.62) 0.24‡
*From the stratified Cox regression model classifying response as a time-varying covariate, stratified by FAB and IPSS. †Similar results were obtained using the stratified Cox regres-
sion with terms ECOG, PS, baseline LDH, baseline Hgb, number of RBC transfusions in the 56 days before randomization, and the presence or absence of -7/del(7q) abnormality.
‡The observed significant survival benefit is mediated only through the other factors in the model. HI: hematologic improvement; SD: stable disease; PR: partial remission; CR: com-
plete remission.
Table 3. Kaplan-Meier estimates of median OS and OS at 2 years in patients who achieved an overall response and in patients with stable disease
as a best response.
AZA CCR AZA vs. CCR 2-year survival
Time Median OS*† Median OS*† Hazard Ratio AZA % of Pts CCR % of Pts 
point months (95% CI) months (95% CI) (95% CI) (95% CI) (95% CI)
Overall Response (HI, CR, or PR)
3 Months n=56 n=30 0.26 (0.13, 0.53) 76% (60%, 86%) 33% (16%, 52%)
>33 (25, NE) 17 (12, 24)
6 Months n=68 n=28 0.31 (0.15, 0.65) 73% (57%, 84%) 34% (14%, 55%)
>33 (25, NE) 20 (17, 24)
9 Months n=63 n=21 0.27 (0.11, 0.67) 83% (67%, 92%) 42% (18%, 65%)
>35 (26, NE) 22 (18, 26)
Stable Disease as best response
3 Months n=93 n=92 0.71 (0.46, 1.1) 52% (40%, 63%) 33% (22%, 45%)
26 (18, NE) 18 (16, 22)
6 Months n=49 n=41 0.92 (0.43, 2.0) 63% (46%, 76%) 57% (36%, 74%)
35 (19, NE) >35 (22, NE)
9 Months n=23 n=21 0.58 (0.14, 2.5) 84% (59%, 95%) 63% (31%, 84%)
>36 (35, NE) >35 (22,NE)
*Overall follow up was 21.1 months. †Survival estimates were obtained using Kaplan-Meier methods. NE: not estimable.
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needed to clarify our findings. Whether to continue azaci-
tidine treatment after six cycles in patients with SD
remains uncertain, but may be clarified in a prospective,
randomized discontinuation trial. The physician’s decision
to continue azacitidine treatment in patients with stable
disease, is best made in collaboration with the patient,
taking tolerance, toxicity, and treatment-related quality of
life into consideration.
Assessing the relationship between response and OS is
subject to known biases, e.g. patients with longer OS have
more time to attain better responses. To minimize biases,
a Cox regression analysis with response as a time-varying
covariate supported by landmark analyses is recommend-
ed when assessing OS-response relationships.9-11 These
two different analytic approaches reached similar conclu-
sions in this analysis. Nevertheless, there are acknowl-
edged limitations to analyses of OS by response in gener-
al10 and in MDS in particular. The possibility that response
is a marker of intrinsically good prognosis rather than
treatment effect cannot be excluded.10 In MDS, rates of
disease progression vary. In some cases, Stable Disease
may reflect variability in disease course rather than a ther-
apeutic effect. In addition, the multivariate analysis is lim-
ited in that it accounts for patient status at each assess-
ment, regardless of previous status, e.g. Stable Disease
after CR is treated the same as Stable Disease without
prior response. This limitation is addressed somewhat by
results of the landmark analyses which provide OS esti-
mates only for patients alive and on-study at each land-
mark with response categorized at that landmark, and by
results of the sensitivity analysis showing that presence or
absence of investigator-reported CR or PR did not influ-
ence the significant improvement in OS in patients with
HI or Stable Disease as their best treatment response. 
These are the first results from a large, phase III con-
trolled trial to clearly demonstrate that a response of HI
with azacitidine is associated with significantly pro-
longed OS compared with CCR in patients with higher-
risk MDS.
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